European Neurologists’ Opinions on Alzheimer’s Disease

Alzheimer's disease (AD) remains a critical area in healthcare research, demanding timely diagnosis and advanced care options. A new survey among European neurologists underscores the imperatives of early detection, the significance of primary care gateways, and the essential role of innovation in transforming AD management.

Key findings include:

• 83% of surveyed neurologists believe that pharmaceutical innovation will have a significant positive impact on Alzheimer's disease patients and their families
• 87% of surveyed neurologists agree that diagnosing AD early during Mild Cognitive Impairment (MCI) or Mild Dementia stages offers patients significantly better care options
• 97% of neurologists surveyed report that patients or their families often attempt to hide or downplay dementia symptoms during initial consultations
• PCPs are recognised by 75% of neurologists as playing a critical role in detecting and referring patients with memory complaints. However, 53% of surveyed neurologists consider PCPs not knowledgeable enough about AD

Authors and contributors to the report across Ipsos are:

• Helen Bennis
• Rebecca West
• Laura McBride
• Alexandra Deku

Technical note
On behalf of Eli Lilly and Company, Ipsos UK conducted an online survey among 400 neurologists across four countries (France, Italy, Spain, Germany; n=100 in each country) between 4th July and 30th July 2025. All voluntarily chose to participate. All respondents had been medically qualified for 3-30 years, spent the majority of their clinical time in a hospital setting, spent at least 60% of their professional time in direct patient care, and were actively treating patients with AD. The overall total results are based on a global average across the four countries, and data was weighted equally across the surveyed countries.